Dibekacin


Generic Medicine Info
Indications and Dosage
Parenteral
Susceptible infections
Adult: 1-3 mg/kg daily by IM or slow IV infusion in divided doses. Adjust dose based on serum monitoring.
Contraindications
Pregnancy; hypersensitivity; known or suspected perforation of the eardrum (topical application into the ear).
Special Precautions
Myasthenia gravis; regular assessment of auditory and renal function is necessary in patients with additional risk factors. Monitoring is important in patients on high doses or prolonged courses, impaired renal function; infants, elderly, obese, cystic fibrosis.
Adverse Reactions
Ototoxicity; nephrotoxicity; acute renal failure, decreased glomerular filtration rate; electrolyte disturbances; respiratory depression; muscular paralysis; hypersensitivity reactions; atrophy or fat necrosis at Inj sites; cross-sensitivity with other aminoglycosides.
Drug Interactions
Other nephrotoxic drugs e.g. vancomycin, cephalosphorins, ciclosporin, cisplatin and fludarabine; potentially ototoxic drugs e.g. ethacrynic acid, furosemide; neuromuscular-blocking agents; general anaesthetics; opioids; β-lactams; dimenhydrinate.
Action
Description: Dibekacin is an aminoglycoside derived from kanamycin. It binds to 30s and 50s subunits of bacterial ribosome thus inhibiting protein synthesis and generating errors in genetic code transcription causing cell death. It acts against gram-negative aerobes and some strains of Staphylococci.
MIMS Class
Aminoglycosides
Disclaimer: This information is independently developed by MIMS based on Dibekacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in